By: IPP Bureau
Last updated : February 20, 2022 3:10 pm
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
Natco Pharma reported a 28.23% growth in net profit to Rs 80.40 crore for the quarter ended December 31, 2021 as compared to Rs 62.70 crore during the corresponding quarter in FY21.
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22 against Rs 386 crore for the previous corresponding quarter, reflecting a growth of 53.03% yoy.
The company reported an EBITDA of Rs 132 crore for the quarter ended December 2021, as compared to Rs113.30 crore for the previous corresponding quarter, registering a growth of 16.50% yoy.
EBITDA margin for the quarter narrowed to 22.3% for the quarter ended December 2021, against 29.40% for the previous corresponding quarter. PAT margin was 13.6% for Q3FY22 against 16.2% for Q3FY21.
Natco’s total revenue consists of API Revenue at Rs 61.70 crore, Formulation revenue at Rs 483.40 crore, and revenue from crop health sciences was Rs0.30 crore, and other operating & non-operating incomes stood at Rs 45.30 crore.